News coverage about Corcept Therapeutics (NASDAQ:CORT) has been trending somewhat positive this week, Accern Sentiment reports. The research group rates the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Corcept Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 46.159610218254 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

CORT has been the subject of a number of research reports. Ladenburg Thalmann Financial Services set a $20.00 price target on Corcept Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, July 18th. Zacks Investment Research upgraded Corcept Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, July 11th. BidaskClub upgraded Corcept Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Friday, August 18th. Stifel Nicolaus initiated coverage on Corcept Therapeutics in a research note on Thursday, August 31st. They issued a “buy” rating and a $20.00 price target for the company. Finally, Piper Jaffray Companies lifted their price target on Corcept Therapeutics from $18.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, September 8th. One analyst has rated the stock with a sell rating, four have given a buy rating and two have issued a strong buy rating to the company. Corcept Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $16.17.

Corcept Therapeutics (NASDAQ CORT) traded up 0.20% during trading on Thursday, reaching $19.61. The company had a trading volume of 121,421 shares. The stock has a market cap of $2.22 billion, a P/E ratio of 97.56 and a beta of 2.12. Corcept Therapeutics has a 12-month low of $6.11 and a 12-month high of $19.83. The firm has a 50-day moving average price of $17.07 and a 200 day moving average price of $12.87.

Corcept Therapeutics (NASDAQ:CORT) last announced its quarterly earnings data on Tuesday, August 1st. The biotechnology company reported $0.10 EPS for the quarter, beating the Zacks’ consensus estimate of $0.08 by $0.02. The business had revenue of $35.56 million during the quarter, compared to analyst estimates of $31.37 million. Corcept Therapeutics had a net margin of 22.28% and a return on equity of 51.45%. The firm’s revenue for the quarter was up 80.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.01 earnings per share. Equities research analysts predict that Corcept Therapeutics will post $0.42 EPS for the current fiscal year.

In related news, Director David L. Mahoney sold 23,006 shares of the stock in a transaction dated Wednesday, July 19th. The shares were sold at an average price of $12.50, for a total value of $287,575.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director David L. Mahoney sold 6,510 shares of the stock in a transaction dated Wednesday, July 12th. The stock was sold at an average price of $12.50, for a total transaction of $81,375.00. The disclosure for this sale can be found here. Insiders sold 42,601 shares of company stock valued at $532,513 in the last three months. Company insiders own 19.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This report was first reported by Watch List News and is the property of of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at

About Corcept Therapeutics

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR).

Insider Buying and Selling by Quarter for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.